Cargando…

Phase I/II trial of doxorubicin and fixed dose-rate infusion gemcitabine in advanced soft tissue sarcomas: a GEIS study

The aim of the study was to determine the dose-limiting toxicity and maximum tolerated dose of a first-line combination of doxorubicin and gemcitabine in adult patients with advanced soft tissue sarcomas and to explore its activity and toxicity, and the presence of possible interactions between thes...

Descripción completa

Detalles Bibliográficos
Autores principales:	López-Pousa, A, Losa, R, Martín, J, Maurel, J, Fra, J, Sierra, M, Casado, A, García del Muro, J, Poveda, A, Balañá, C, Martínez-Trufero, J, Esteban, E, Buesa, J M
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2006
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361345/ https://www.ncbi.nlm.nih.gov/pubmed/16721358 http://dx.doi.org/10.1038/sj.bjc.6603187

Ejemplares similares

GEIS-21: a multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of Ewing sarcoma of children and adults: a report from the Spanish sarcoma group (GEIS)
por: Mora, J, et al.
Publicado: (2017)

Phase II Trial of Doxorubicin Plus Escalated High-Dose Ifosfamide in Patients With Advanced Soft Tissue Sarcomas of the Adult: A Study of the Spanish Group for Research on Sarcomas (GEIS)
por: López-Pousa, A., et al.
Publicado: (2006)

Phase II Clinical Trial With Pegylated Liposomal Doxorubicin (CAELYX®/Doxil®) and Quality of Life Evaluation (EORTC QLQ-C30) in Adult Patients With Advanced Soft Tissue Sarcomas: A study of the Spanish Group for Research in Sarcomas (GEIS)
por: Poveda, A., et al.
Publicado: (2005)

Phosphorylated-insulin growth factor I receptor (p-IGF1R) and metalloproteinase-3 (MMP3) expression in advanced gastrointestinal stromal tumors (GIST). A GEIS 19 study
por: Maurel, Joan, et al.
Publicado: (2016)

GEIS 2013 guidelines for gastrointestinal sarcomas (GIST)
por: Poveda, Andrés, et al.
Publicado: (2014)

2023 GEIS Guidelines for gastrointestinal stromal tumors
por: Serrano, César, et al.
Publicado: (2023)

Malignant bone tumors (other than Ewing’s): clinical practice guidelines for diagnosis, treatment and follow-up by Spanish Group for Research on Sarcomas (GEIS)
por: Redondo, Andrés, et al.
Publicado: (2017)

Updated Review and Clinical Recommendations for the Diagnosis and Treatment of Patients with Retroperitoneal Sarcoma by the Spanish Sarcoma Research Group (GEIS)
por: Álvarez Álvarez, Rosa, et al.
Publicado: (2023)

Capacity-building efforts by the AFHSC-GEIS program
por: Sanchez, Jose L, et al.
Publicado: (2011)

A Growth Modulation Index-Based GEISTRA Score as a New Prognostic Tool for Trabectedin Efficacy in Patients with Advanced Soft Tissue Sarcomas: A Spanish Group for Sarcoma Research (GEIS) Retrospective Study
por: Martínez-Trufero, Javier, et al.
Publicado: (2021)

Dose-finding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patients
por: Abajo, A, et al.
Publicado: (2010)

Clinical practice guidelines for the diagnosis and treatment of patients with soft tissue sarcoma by the Spanish group for research in sarcomas (GEIS)
por: Garcia del Muro, Xavier, et al.
Publicado: (2015)

SEOM Clinical Guideline of management of soft-tissue sarcoma (2016)
por: López-Pousa, A., et al.
Publicado: (2016)

Antimicrobial resistance surveillance in the AFHSC-GEIS network
por: Meyer, William G, et al.
Publicado: (2011)

Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma
por: Bengala, C, et al.
Publicado: (2005)

Gemcitabine in Bone Sarcoma Resistant to Doxorubicin-Based Chemotherapy
por: Merimsky, Ofer, et al.
Publicado: (2000)

A growing global network’s role in outbreak response: AFHSC-GEIS 2008-2009
por: Johns, Matthew C, et al.
Publicado: (2011)

Gemcitabine fixed-dose rate infusion for the treatment of pancreatic carcinoma: a meta-analysis of randomized controlled trials
por: Xie, Jiqing, et al.
Publicado: (2014)

Treated Incidence of Psychotic Disorders in the Multinational EU-GEI Study
por: Jongsma, Hannah E., et al.
Publicado: (2017)

SEOM-GEIS clinical guideline for gastrointestinal stromal tumors (2022)
por: Serrano, César, et al.
Publicado: (2023)

CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone
por: Wasan, H S, et al.
Publicado: (2009)

Migration history, first episode psychosis and child abuse: Results from the EU-GEI study
por: Tarricone, I., et al.
Publicado: (2021)

Uterine sarcomas: clinical practice guidelines for diagnosis, treatment, and follow-up, by Spanish group for research on sarcomas (GEIS)
por: Pérez-Fidalgo, Jose Alejandro, et al.
Publicado: (2023)

Genetic and psychosocial stressors have independent effects on the level of subclinical psychosis: findings from the multinational EU-GEI study
por: Pignon, B., et al.
Publicado: (2022)

Trabectedin and RAdiotherapy in Soft Tissue Sarcoma (TRASTS): Results of a Phase I Study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups
por: Gronchi, Alessandro, et al.
Publicado: (2019)

Detection of subclinical cardiotoxicity in sarcoma patients receiving continuous doxorubicin infusion or pre-treatment with dexrazoxane before bolus doxorubicin
por: Li, Jieli, et al.
Publicado: (2020)

Migration history and risk of psychosis: results from the multinational EU-GEI study
por: Tarricone, Ilaria, et al.
Publicado: (2022)

High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group.
por: Nielsen, O. S., et al.
Publicado: (1998)

REGISTRI: Regorafenib in first-line of KIT/PDGFRA wild type metastatic GIST: a collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial
por: Martin-Broto, Javier, et al.
Publicado: (2023)

The AFHSC-Division of GEIS Operations Predictive Surveillance Program: a multidisciplinary approach for the early detection and response to disease outbreaks
por: Witt, Clara J, et al.
Publicado: (2011)

Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer
por: D'Agostino, G, et al.
Publicado: (2003)

Prolonged low-dose infusion for gemcitabine: a systematic review
por: Zhao, Dehua, et al.
Publicado: (2019)

Gemcitabine, Navelbine, and Doxorubicin as Treatment for Patients with Refractory or Relapsed T-Cell Lymphoma
por: Qian, Zhengzi, et al.
Publicado: (2015)

In Vivo Evaluation of the Anticancer Activity of the Gemcitabine and Doxorubicin Combined in a Nanoemulsion
por: Alkhatib, Mayson H., et al.
Publicado: (2018)

Prognostic Impact of let-7e MicroRNA and Its Target Genes in Localized High-Risk Intestinal GIST: A Spanish Group for Research on Sarcoma (GEIS) Study
por: Fernandez-Serra, Antonio, et al.
Publicado: (2020)

Enteric disease surveillance under the AFHSC-GEIS: Current efforts, landscape analysis and vision forward
por: Money, Nisha N, et al.
Publicado: (2011)

Transdiagnostic dimensions of psychopathology at first episode psychosis: findings from the multinational EU-GEI study
por: Quattrone, Diego, et al.
Publicado: (2019)

Synergistic effects of childhood adversity and polygenic risk in first-episode psychosis: the EU-GEI study
por: Aas, Monica, et al.
Publicado: (2023)

Gemcitabine with Cisplatin Versus Hepatic Arterial Infusion Pump Chemotherapy for Liver-Confined Unresectable Intrahepatic Cholangiocarcinoma
por: Franssen, Stijn, et al.
Publicado: (2023)

SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours
por: Khatri, A, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_1v59ntpisk7v4c7oh3cd9bqnok